Clinical Trial Update: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IMM01 plus Tiselizumab versus physician's choice chemotherapy in PD-L1-refractory classical Hodgkin lymphoma; study status is not yet r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• IMM01 (IMM01)
• Tiselizumab (Tiselizumab)

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: Classic Hodgkin Lymphoma | Phase 3 | Status: NOT_YET_RECRUITING